Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
KEYTRUDA (Merck Sharp & Dohme (Australia) Pty Ltd)
Product name
KEYTRUDA
Date registered
Evaluation commenced
Decision date
Approval time
173 working days (255)
Active ingredients
pembrolizumab
Registration type
EOI
Indication
Renal Cell Carcinoma
KEYTRUDA® (concentrated injection; powder for injection) in combination with axitinib, is now also indicated for the first-line treatment of patients with advanced renal cell carcinoma (RCC).